Among the many oncology therapies, few have generated as much excitement as CAR-T.
The success of CAR therapy would not have been possible without the many discoveries …

Objective We analyzed the characteristics and risk factors for pulmonary infection in patients
with spinal cord injury who underwent tracheostomy and propose measures to help in early …

Chimeric antigen receptor T-cells (CAR-T) are now a standard approach for treating
relapsed/refractory B-cell lymphomas. Immune effector cell-associated hemophagocytic …

Simple Summary Targeted therapies have revolutionized the management of hematological
malignancies and solid organ cancers. These new treatments present numerous infectious …

Chimeric antigen receptor T-cell (CAR-T) therapy has shown remarkable effects in treating
various hematological malignancies. However, hematotoxicity, specifically neutropenia …

Understanding the immune response to Aspergillus fumigatus, a common cause of invasive
fungal infections (IFIs) in immunocompromised individuals, is critical for developing effective …

CAR-T therapy has revolutionized the treatment of relapsed/refractory B-cell malignancies.
Patients who are receiving such therapy are susceptible to an increased incidence of …

Genetically engineered chimeric antigen receptor (CAR) T cells have become an effective
treatment option for several advanced B-cell malignancies. Haematological side-effects …

Chimeric antigen receptor T-cell therapy (CAR-T) has been widely applied in the clinical
practice of relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) due to its …

Résumé Les infections survenant après CAR-T cells, sont une complication relativement
fréquente, même si leur incidence exacte est inconnue, notamment du fait de la distinction …